Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc. (HALO)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025 (Event Date: November 12, 2025)
Context: The Company completed a significant capital raise through the issuance of convertible senior notes and entered into related hedging transactions.
Key Financial Metrics
| Metric | Value |
|---|---|
| Total Principal Amount Issued | $1,500.0 million |
| Net Proceeds Received | Approximately $1.47 billion |
| Cost of Capped Call Transactions | Approximately $182.7 million |
| Cash Paid for Note Repurchases | Approximately $1.020 billion (includes accrued interest) |
| Conversion Price | Approximately $87.20 per share |
| Initial Conversion Rate | 11.4683 shares per $1,000 principal |
Material Changes and Transaction Details
Convertible Notes Issuance
- 2031 Convertible Notes: $750.0 million aggregate principal (including $100.0 million option exercise). 0% interest rate. Due 2031.
- 2032 Convertible Notes: $750.0 million aggregate principal (including $100.0 million option exercise). 0.875% interest rate payable semi-annually starting May 15, 2026. Due 2032.
- Structure: Unsecured obligations ranking equally with existing unsubordinated debt. Convertible into cash and/or common stock at the Company's election.
Debt Repayment
- The Company utilized a portion of the net proceeds to repurchase outstanding 2027 Convertible Notes (0.25%) and 2028 Convertible Notes (1.00%) via privately negotiated transactions.
- Total cash outflow for these repurchases was approximately $1.020 billion.
Capped Call Transactions
- Entered into capped call transactions to reduce potential dilution from the convertible notes.
- Cap Price: $136.78 per share (100% premium over the November 5, 2025 closing price).
- Cost of $182.7 million was funded from the offering proceeds.
Outlook, Risks, and Management Commentary
Use of Proceeds
After funding the capped call transactions and repurchasing existing notes, the remainder of the net proceeds will be used for general corporate purposes, including working capital, capital expenditures, potential acquisitions, strategic transactions, and potential future note repurchases.
Key Risks and Terms
- Conversion Triggers: Holders may convert notes during specific quarters if the stock price exceeds 130% of the conversion price, or during specific periods if the trading price falls below 98% of the conversion value.
- Redemption: The Company cannot redeem the 2031 Notes prior to February 20, 2029, or the 2032 Notes prior to November 20, 2029.
- Fundamental Change: Holders may require the Company to repurchase notes upon a "Fundamental Change" at 100% of principal plus accrued interest.
- Market Impact: Counterparties to the capped call transactions may hedge their positions by trading the Company's stock, which could affect the market price.
Investor Verification Checklist
- Verify the exact amount of existing 2027 and 2028 notes remaining outstanding after the $1.020 billion repurchase.
- Confirm the specific terms of the "Fundamental Change" definition in the attached Indentures (Exhibits 4.1 and 4.3).
- Review the impact of the $182.7 million cost of the capped call transactions on the Company's immediate cash balance.
- Monitor the Company's stock price relative to the $87.20 conversion price and the $136.78 cap price to assess dilution risk.
- Check for any subsequent filings regarding the completion of the repurchase of the Existing Convertible Notes.